Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis

BACKGROUND: Atherosclerosis is a chronic inflammatory disease responsible for most cases of heart disease and stroke in Western countries. The cytotoxic drug cyclophosphamide (CPA) can modulate immune functions, and it has therefore been used to treat patients with autoimmune diseases. Extension of...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato-Okabayashi, Yayoi, Isoda, Kikuo, Heissig, Beate, Kadoguchi, Tomoyasu, Akita, Koji, Kitamura, Kenichi, Shimada, Kazunori, Hattori, Koichi, Daida, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300380/
https://www.ncbi.nlm.nih.gov/pubmed/32577494
http://dx.doi.org/10.1016/j.ijcha.2020.100529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300380/
https://www.ncbi.nlm.nih.gov/pubmed/32577494
http://dx.doi.org/10.1016/j.ijcha.2020.100529

Ejemplares similares